Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Altagracia
M
M
Universidad Autónoma Metropolitana-Xochimilco, Departamento de Sistemas Biológicos, México, D.F.
Rojas
P
P
Kravzov
J
J
Rios
C
C
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000031:analogs & derivatives*; D000547:Amantadine / Q000494:pharmacology*; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008297:Male; D051379:Mice; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism*; D011339:Probenecid / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism*
D015259:Dopamine Agents; C048977:1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000547:Amantadine; D011339:Probenecid; D004298:Dopamine; D006719:Homovanillic Acid